source
- Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCOMerck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…
- Replimune to file third FDA application for RP1 cancer therapy after productive talksReplimune announced it will submit a third marketing application for its experimental cancer therapy RP1, following what the company described as productive discussions with the Food and Drug Admin…